Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Amal El-Gayar"'
Publikováno v:
Cell Death and Disease, Vol 15, Iss 8, Pp 1-16 (2024)
Abstract Hepatocellular carcinoma (HCC) has risen as the villain of cancer-related death globally, with a usual cruel forecasting. Sorafenib was officially approved by the FDA as first-line treatment for advanced HCC. Despite the brilliant promise re
Externí odkaz:
https://doaj.org/article/274737e1103d4eecafbff6d2caa7a039
Publikováno v:
Bulletin of Pharmaceutical Sciences. Assiut.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74a1841cf2ec71648e701a080f2c19f7
https://doi.org/10.21608/bfsa.2023.187768.1650
https://doi.org/10.21608/bfsa.2023.187768.1650
Hepatocellular carcinoma (HCC) has risen as the villain of cancer-related death globally, with a usual cruel forecasting. For advanced HCC, sorafenib has been FDA approved as first line treatment. In spite of the bright potential that sorafenib demon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f1658642e2c3c625bc81c7713f838be
https://doi.org/10.21203/rs.3.rs-2573418/v1
https://doi.org/10.21203/rs.3.rs-2573418/v1
